장마감
로그인 회원가입
NBTX
NBTX
Nanobiotix ADR
7월 27일 4:00 PM ET (한국 7/28 05:00)
$40.08
+0.38 ▲ +0.94%
🌙 7월 27일 5:23 PM ET (한국 7/28 06:23)
$40.18
+0.00 +0.00%

나노바이오틱스(NBTX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$2.0B
스몰캡
P/E
-
배당수익률
없음
52주 위치
67%
저점 +558% · 고점 -30%
애널리스트
적극 매수
C
Fundamental health
vs. 초고성장주 소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 51%
밸류에이션
데이터 부족
재무 안정
Top 57%
Index -P/E -EPS (ttm) -0.57Insider Own 19.6%Shs Outstand 48.4MPerf Week 12.16%
Market Cap 2.03BForward P/E -EPS next Y -25.38%Insider Trans -Shs Float 40.7MPerf Month 16.4%
Enterprise Value 2.08BPEG -EPS next Q -Inst Own 0.15%Short Float 0.21%Perf Quarter 19.34%
Income -0.03BP/S 61.97EPS this Y 57.68%Inst Trans 8.28%Short Ratio 0.9Perf Half Y 91.38%
Sales 0.03BP/B -EPS next 5Y -ROA -Short Interest 0.08MPerf YTD 73.33%
Book/sh -2.05P/C 32.73EPS past 3/5Y 30.98% 18.47%ROE -52W High -29.87% ($57.14)Perf Year 488.47%
Cash/sh 1.22P/FCF -Sales past 3/5Y - 257.86%ROIC -359.34%52W Low 558.05% ($6.09)Perf 3Y 386.94%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 28.27%Gross Margin -Volatility(W/M) 7.56% 6.47%Perf 5Y 193.05%
Dividend TTM -EV/Sales 63.5Sales Y/Y TTM -Oper. Margin -49.09%ATR (14) 2.69Perf 10Y -
Dividend Ex-Date -Quick Ratio 1.09EPS Q/Q 10.74%Profit Margin -84.17%RSI (14) 54.24Recom 1.25
Dividend Gr. 3/5Y -Current Ratio 1.09Sales Q/Q -17.45%SMA20 2.73% ($39.01)Beta 0.77Target Price $55.53
Payout -Debt/Eq -Earnings 2026/3/31SMA50 2.87% ($38.96)Rel Volume 1.01Prev Close $39.7
Employees 97LT Debt/Eq -EPS/Sales Surpr. -248.07% -87.15%SMA200 35.5% ($29.58)Avg Volume(3M) 0.09MPrice $40.08
IPO 2020/12/11Option/Short No/YesTrades 1224Volume 95,237Change 0.94%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Nanobiotix ADR (NBTX) Investment Analysis

What kind of company is Nanobiotix ADR?

나노바이오틱스(NBTX) 초고성장주
Healthcare · Biotechnology
Healthcare Stocks

A clinical-stage biotech company developing nanotechnology-based cancer therapies. It develops nanoparticle-based drug candidates designed to enhance the effectiveness of radiation therapy, targeting a broad range of solid tumors, and has a lead candidate in late-stage clinical development. The company is pursuing entry into the oncology market through a differentiated nano-medicine approach that combines with radiation therapy.

Learn more about Nanobiotix ADR →
Market Cap
$2.0B
Approx. KRW 2.8 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank2097
Employees97people
IPO2020/12/11
Current Price$40.08 ≈ 54,910원
NASD · France

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 3월 31일 (화) · 장 마감 후 EPS -248.1% 매출 -87.2%

Is it profitable?

Profitability weak
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-49.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-84.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-359.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
1.09
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.09
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$55.53
현재가 대비 +38.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
-25.4%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
1
예상 하회
0%
상회 비율
-248.1%
평균 서프라이즈
2026.03.31
하회
-248.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow
Historical growth is expected to lose momentum
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+57.7%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 51.6% · Top 47%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-25.4%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 33.7% · Bottom tier
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+31.0%
우수
My positionTop 25%
Low range Average High range
초고성장주 소형주 Median 6.9% · Top 25%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+18.5%
양호
My positionMid-range
Low range Average High range
초고성장주 소형주 Median 7.0% · Top 35%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+257.9%
우수
My positionTop 5%
Low range Average High range
초고성장주 소형주 Median 32.4% · Top tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-17.4%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 소형주 Median 14.5% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Outperformed the market by 125%p over 5 years
NBTX +193.1% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+124.7%p
well ahead of the market
vs Health Care (XLV)
+168.6%p
well ahead of the sector average
1-year basis
vs S&P 500
+472.5%p
well ahead of the market
vs Health Care (XLV)
+468.8%p
well ahead of the sector average
Rank among peers
5-year return Top among peers Based on 123 peers
1-year return Top among peers Based on 154 peers
Current position within 52-week range
Low (-558.0%p) High (-29.9%p)
Current price is 558.0% above the 52-week low and 29.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-39.1%
Annualized volatility
94.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $40.08 above the midline ($38.98). Normal upward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.479 > Signal 0.362 in positive zone + Hist positive (+0.116). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 54.4 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 67.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
61.97x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 소형주 median 14.61x · Bottom 25% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$55.53 vs. current price +38.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow is positive
Institutional net buying +8.3% · Short interest light 0.2%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+8.3%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 0.1%
Retail-led
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 19.6%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 80.3%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
0.2%
Low — limited short-side pressure
Healthcare 소형주 Median 11.2%
Past 90 days Little change
Short interest days to cover
0.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 48.4M주
Float (tradable shares) 40.7M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding NBTX

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
NBTX NBTX This Stock
$2.0B- - - - +0.9%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 나노바이오틱스(NBTX)?

나노바이오틱스(NBTX) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of NBTX?

The market cap of NBTX is approximately $2.0B, ranking 2,097 within its sector.

What is the 52-week high and low for NBTX?

NBTX has recorded a 52-week high of $57.14 and a low of $6.09.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.